TCL1A

Across TCGA pan-cancer cohorts, TCL1A mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated TCL1A data layer compared with 21 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher TCL1A mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated TCL1A expression acts as an unfavorable survival marker, although some lineages such as LUAD and LSCC show a favorable association.

LUAD, HNSC, and LSCC are the cancer types where TCL1A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Quartile	All	0.933	0.219	<.001	30	view →
HNSC	DFS	Quartile	All	0.868	1.000	.008	12	view →
LSCC	DFS	Median	All	1.000	0.544	.011	5	view →
PDAC	OS	Tertile	III,IV	0.323	0.975	.036	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

TCL1A–LUAD (DFS)

Open the LUAD breakdown →